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Bothrops lanceolatus snake venom causes systemic thrombotic syndrome but also local inﬂammation involving extensive oedema,
pain, and haemorrhage. Systemic thrombotic syndrome may lead to fatal pulmonary embolism and myocardial and cerebral
infarction. Here, we investigated the ability of B. lanceolatus venom to activate the Complement system (C) in order to improve
the understanding of venom-induced local inﬂammation. Data presented show that B. lanceolatus venom is able to activate all
C-pathways. In human serum, the venom strongly induced the generation of anaphylatoxins, such as C5a and C4a, and the
Terminal Complement complex. The venom also induced cleavage of puriﬁed human components C3, C4, and C5, with the
production of biologically active C5a. Furthermore, the venom enzymatically inactivated the soluble C-regulator and the
C1-inhibitor (C1-INH), and signiﬁcantly increased the expression of bound C-regulators, such as MCP and CD59, on the
endothelial cell membrane. Our observations that B. lanceolatus venom activates the three Complement activation
pathways, resulting in anaphylatoxins generation, may suggest that this could play an important role in local inﬂammatory
reaction and systemic thrombosis caused by the venom. Inactivation of C1-INH, which is also an important inhibitor of
several coagulation proteins, may also contribute to inﬂammation and thrombosis. Thus, further in vivo studies may
support the idea that therapeutic management of systemic B. lanceolatus envenomation could include the use of
Complement inhibitors as adjunct therapy.
1. Introduction
Snakes from the genus Bothrops are responsible for the
majority of venomous ophidian accidents in South and
Central America [1]. They induce a complex pathophysiol-
ogy, referred to as bothropic syndrome. After envenomation,
haemorrhage, pain, and oedema appear quickly at the site of
the bite, whereas coagulation disturbances, haemorrhage,
and renal failure are commonly observed systemic symptoms
[2]. Dermonecrosis, myonecrosis, and local infection can
cause disabling sequels [3, 4].
Bothrops lanceolatus, commonly named Martinique
lancehead (“Fer-de-lance”), is a native species conﬁned to
the Caribbean island of Martinique. Systemic clinical
symptoms of B. lanceolatus envenomation diﬀer from
envenomation by other Bothrops species as it is character-
ized by a predominant prothrombotic proﬁle and is rarely
haemorrhagic [2]. In approximately 30–40% of the cases,
multiple arterial thrombi occur, which is unique to B. lan-
ceolatus and B. carribeus, a Bothrops species from the
neighbouring island of Saint Lucia. This can lead to death
due to myocardial and cerebral infarction or pulmonary
oedema [5]. Local eﬀects are comparable to the bothropic
syndrome involving prominent oedema, pain, and haem-
orrhage from the fang marks. In case of envenomation,
only rapid treatment with the monospeciﬁc commercial
antivenom, raised against B. lanceolatus venom (Bothrofav®,
Sanoﬁ Pasteur, France), can prevent the development of
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systemic thrombosis, which if untreated can result in death
[5, 6]. But even this antivenom is not always eﬀective and
supplementary therapies may be beneﬁcial to the patient
[6]. Thus, a better understanding of how this venom causes
pathology is required.
Bothrops snake venoms are complex mixtures of bioac-
tive organic and inorganic components, such as proteins,
peptides, carbohydrates, lipids, and mineral salts. These
venoms display a wide range of interspecies variations both
in composition and biological activities [7–12]. Metallo-
and serine proteases are among the most abundant enzymes
found in Bothrops venoms. They play a central part in the
local and systemic development of the pathophysiology of
envenomation, respectively, by inducing haemorrhage, myo-
necrosis, inﬂammation, cutaneous lesions, and haemostasis
disturbances [12–15].
The Complement (C) system, a complex group of more
than 50 blood-circulating and cell-surface-expressed and
intracellular proteins, is an important eﬀector mechanism
of innate and adaptive immunity [16]. Ampliﬁcation of the
inﬂammatory response, phagocytosis, lysis of pathogenic
agents, and recognition of altered self are a few of the biolog-
ical processes in which the Complement system is involved
[17–20]. Once activated, a chain reaction of proteolysis and
assembly of protein complexes evolves, which is ﬁnely
regulated by soluble and membrane-bound regulators [21].
Complement activation can be initiated through any of its
three activation pathways: classical (CP), alternative (AP),
or lectin (LP), all converging towards the formation of C3-
convertases and the cleavage of C3 component into C3b
and the anaphylatoxin C3a. C3b is involved in the formation
of the C5-convertase, which in turns cleaves C5 into C5b and
the anaphylatoxin C5a. C5b interacts with C6, C7, C8, and
several C9 proteins to form the membrane attack complex
(C5b-9 or MAC), which generates a lytic pore in the target
membrane. The anaphylatoxins C3a, C4a, and C5a constitute
potent proinﬂammatory mediators, via the interaction with
speciﬁc receptors such as C3aR and C5aR1 [22]. The activa-
tion of the Complement cascade is regulated by membrane
proteins including Complement-receptor 1 (CR1), mem-
brane cofactor protein (MCP/CD46), decay-accelerating fac-
tor (DAF/CD55), and CD59. Factor I, Factor H, Factor-H
related proteins, C4-binding protein (C4BP), and C1-
inhibitor (C1-INH) are important soluble regulators of
Complement [23–26].
Inappropriate activation of the Complement cascade can
be harmful to the host and can lead to inﬂammation and
thrombosis [27]. Numerous animal venoms interact with
the human Complement system, for example, by initiating
the C-cascade activation, as shown for venoms of 19 diﬀerent
Bothrops species from South and Central America [28, 29]. In
these studies, we showed that Bothrops venoms triggered the
C-cascade by one or several activation pathways, generating
high quantities of anaphylatoxins by directly cleaving C3
and C5 or by inactivating the regulator C1-INH. These
events involved both metalloproteases and serine proteases.
No modiﬁcations of the membrane regulators, DAF, CR1,
and CD59, were observed in case of Bothrops venoms expo-
sure [28, 30–32]. The activation of the Complement system
by Bothrops venoms may constitute an important event in
human bothropic envenomation pathophysiology.
B. lanceolatus venom is antigenically similar to other
Bothrops venoms but diﬀers from other Bothrops venoms in
that it does not induce coagulation of human plasma, has
very low hyaluronidase activity, and their proteases have dif-
ferent substrate speciﬁcities [10, 33]. The B. lanceolatus
venom contains glycosylated proteins that could potentially
trigger the lectin Complement pathway [10, 34]. Considering
that the anti-B. lanceolatus antivenom Bothrofav is not
always 100% percent eﬀective at preventing local and sys-
temic events [6], supplementary therapies may be beneﬁcial
to the patient. Thus, a better understanding of how this
venom causes inﬂammation and thrombosis is required.
Considering the important role Complement can play in
inﬂammation and thrombosis, we investigated the poten-
tial of B. lanceolatus to activate the Complement cascade
in vitro, and interact with its proteins, regulators, and
receptors. Here, we show that B. lanceolatus venom activates
Complement cascade, aﬀecting major C-components and
soluble/membrane-bound inhibitors, and inducing the pro-
duction of proinﬂammatory mediators.
2. Material and Methods
2.1. Chemicals, Reagents, and Buﬀers. Tween-20, Dextran
70, ethylene diamine tetraacetic acid (EDTA), ethylene
glycol-bis-(beta-aminoethylether)-N,N,N′,N′-tetraacetic acid
(EGTA), barbituric acid, sodium barbital, ortho-phenylene-
diamine (OPD), phenylmethanesulfonyl ﬂuoride (PMSF),
1,10-phenantroline, mannan, and bovine serum albumin
(BSA) were purchased from Sigma-Aldrich (St. Louis,
MO, USA). Puriﬁed human Complement components C3,
C4, C5, and C1-INH, as well as goat anti-human C4 anti-
body were purchased from Quidel Corporation (San
Diego, CA, USA). Fluo-4 AM was from Life Technologies
(Waltham, MA, USA). The following murine antibodies
against human CD46 (clone E4.3), CD55 (clone IA10),
and CD59 (clone p282-H19) were purchased from BD
Pharmingen (San Diego, CA, USA). Polyclonal goat anti-
mouse IgG-PE, polyclonal rabbit anti-goat IgG labelled with
alkaline phosphatase, and goat anti-human C1-INH anti-
bodies were obtained from Sigma-Aldrich (MO, USA).
Foetal bovine serum (FBS) was from Cultilab (São Paulo,
Brazil). Dulbecco’s modiﬁed Eagle’s medium (DMEM),
penicillin, and streptomycin were from Gibco/Thermo
Fisher Scientiﬁc (Gaithersburg, MD, USA). Buﬀers include
saline solution (150mM NaCl), PBS (8.1Mm Na2HPO4,
1.5mM KH2PO4, 137mM NaCl, and 2.7mM KCl, pH7.2),
Alsever’s solution (114mM citrate, 27mM glucose, 72mM,
and NaCl, pH6.1), Veronal-Buﬀered Saline (VBS2+; 2.8mM
barbituric acid, 145.5mM NaCl, and 0.3mM CaCl2,
pH7.2), AP buﬀer (5mM sodium barbital, 7mM MgCl2,
10mM EGTA, and 150mM NaCl, pH7.4), BVB2+ buﬀer
(VBS2+, 0.5mM MgCl2, 2mM CaCl2, 0.05% Tween-20,
and 0.1% BSA, pH7.5), BSS buﬀer (137mM NaCl,
2.68mM KCl, 78.3mM Na2HPO4, and 1.47mM KH2PO4),
Krebs buﬀer (120mM NaCl, 25mM HEPES, 4.8mM KCl,
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1.2mM KH2PO4, and 1.2mM MgSO4), and FACS buﬀer
(1% BSA, 0.01% NaN3 in PBS).
2.2. Venom. Venom from Bothrops lanceolatus (B. lanceola-
tus) was obtained from Latoxan (Aix-en-Provence, France).
Stock solution was prepared in sterile saline solution at
5mg/mL and stored at −80°C.
2.3. Normal Human Serum, Erythrocytes, and Ethics
Statements. Human blood was obtained by signed consent
from healthy donors. Blood was collected by venepuncture
without anticoagulant and refrigerated for 4 h. After clot
formation, blood was centrifuged at 400×g for 15min at
4°C, serum was collected, aliquoted, and stored at −80°C.
This study was approved by the Human Research Ethics
Committee (HREC) from the Institute of Biomedical Sci-
ences at the University of São Paulo, São Paulo, Brazil (proto-
col approval number 274.313). Sheep and rabbit erythrocytes
were collected in Alsever’s. All the procedures involving ani-
mals were in accordance with the ethical principles in animal
research adopted by the Brazilian Society of Animal Science
and the National Brazilian Legislation number 11.794/08.
Protocols were approved by the Institutional Animal Care
and Use Committee (protocol approval number 1111/13).
2.4. Treatment of Normal Human Serum with B. lanceolatus
Venom. Normal human serum (NHS) was incubated with
the same volume of B. lanceolatus venom in the appropriate
buﬀer (i.e., for CP: VBS2+; AP: APB; and LP: BVB2+), at 37°C
for 30min, to assess eﬀects on the Complement system.
Samples were tested for the remaining Complement activity
or detection of the activation by-product. The role of metal-
loproteases in the venom was investigated by coincubation
with 1,10-phenantroline (10mM).
2.5. Haemolytic Complement Assays. Haemolytic activity was
assessed using sensitized sheep erythrocytes (ES) for the CP
[35], or rabbit erythrocytes (ER) for the AP [28]. CH50 and
AP50 were calculated for each venom concentration. Venom
concentrations able to inhibit 50% (IC50) of the activity of
each pathway and their respective 95% conﬁdence intervals
(CI95%) were determined from the curves of CH50 and
AP50 plotted as a function of the logarithm of venom concen-
tration by nonlinear regression using GraphPad Prism 6.0
software (GraphPad, La Jolla, CA, USA) [32, 35].
2.6. Action of B. lanceolatus Venom on Lectin Pathway. LP
activity was assessed using mannan-coated microtiter plates
and measurement of C4 deposition as previously described
[28]. LP50 was calculated for each venom concentration.
Venom concentrations able to inhibit 50% (IC50) of the
activity of LP and its 95% conﬁdence interval (CI95%) were
determined from the values of LP50 for each venom concen-
tration (see Section 2.5) by nonlinear regression using
GraphPad Prism 6.0 software.
2.7. Detection of Anaphylatoxins and Terminal Complement
Complex (TCC) in Venom-Treated Samples. C3a/C3a-
desArg, C4a/C4a-desArg, and C5a/C5a-desArg were mea-
sured using the Human Anaphylatoxin Cytometric Bead
Array (CBA) (BD Biosciences Pharmingen, San Diego, CA,
USA), following the manufacturer’s instructions. Cytometric
analysis was performed using a FACSCanto-II (Becton Dick-
inson, San Diego, CA, USA), and the data were analysed with
the Flow Cytometric Analysis Program (FCAP) Array 3.0
(Becton Dickinson, San Diego, CA, USA). Anaphylatoxin
concentrations (μg/mL) were determined by linear regres-
sion from the standard curve. TCC (in its soluble form
SC5b-9) was determined using the MicroVue™ SC5b-9 Plus
EIA Kit (Quidel Corporation, San Diego, CA, USA), accord-
ing to the manufacturer’s instructions. TCC concentration
(μg/mL) in the samples was calculated from a linear regres-
sion of the standard curve.
2.8. Cleavage of Puriﬁed Complement Components by B.
lanceolatus Venom. To evaluate the direct cleavage of the
Complement components by the B. lanceolatus venom, puri-
ﬁed human Complement proteins, C3, C4, C5, and C1-INH
(2μg from 0.2mg/mL samples), were incubated with the
same quantity of venom for 30min at 37°C. C1-INH was
incubated with venom in the presence or absence of protease
inhibitors, PMSF (20mM), EDTA (20mM), or 1,10-phenan-
troline (20mM). Samples were then submitted to SDS-PAGE
(10% separating gel) under reducing conditions and silver-
stained to detect cleavage [36, 37]. In addition, cleavage of
C1-INH was also revealed by Western blotting, using goat
anti-human C1-INH antibodies (1 : 2000) and rabbit anti-
goat IgG labelled with alkaline phosphatase (1 : 7500). The
reaction was developed by adding NBT/BCIP, following the
instructions of the manufacturer.
2.9. Inhibitory Activity of C1-INH following Incubation with
B. lanceolatus Venom. C1s-binding activity of C1-INH was
assessed using the MicroVue™ C1-Inhibitor Plus EIA
(Quidel Corporation, CA, USA), according to the manufac-
turer’s procedure. Samples of puriﬁed human C1-INH were
exposed to B. lanceolatus venom. As control, saline-treated
C1-INH samples were used. Following the assay procedure,
samples (diluted 1 : 25) were incubated with biotinylated
C1s (venom concentration of 8μg/mL), and were incubated
on avidine-coated microtiter plates. Horseradish peroxidase-
(HRP-) conjugated goat anti-human C1-INH was added to
each test well and the reaction developed enabling the detec-
tion of C1-INH-C1s complexes deposited on the plates. After
subtraction of the blank, the residual C1-INH-C1s-complex-
ing activity of each sample was expressed as a percentage of
the control sample activity.
2.10. Intracellular Calcium Flux Measurements. Functional
C5a generation was assessed by measuring cytoplasmic cal-
cium release from intracellular stores in leukocytes, of
which neutrophils are the main population and the main
responders, using the calcium indicator Fluo-4 AM. Leuko-
cytes were separated from platelets and red blood cells by
dextran sedimentation from heparinised human blood using
standard procedures. Cells were resuspended in Dulbecco’s
modiﬁed Eagle’s medium (DMEM), 10% heat-inactivated
foetal bovine serum (FBS), and loaded with the ﬂuorescent
calcium indicator Fluo-4 AM (1μM) at 2μg/107 cells/mL,
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at room temperature for 30min. Cells were washed with
BSS and resuspended in Krebs buﬀer containing 0.1%
BSA. Cells (106/well in 200μL Krebs buﬀer) were stimulated
with venom-treated C5 (10μL/well; ﬁnal concentration of
9.5μg/mL), in a 96-well plate and the ﬂuorescence variations
were measured every 3 sec (λex = 485 nm and λem = 510 nm),
using the ﬂuorimeter FLUOstar Omega (BMG Labtech,
Oﬀenburg, Germany). As positive control, cells were
exposed to puriﬁed C5a (10μL/well; ﬁnal concentration
of 11.4 ng/mL) and, as negative controls, cells were exposed
to C5 or venom incubated with saline solution. For each well,
the values of ﬂuorescence were normalized by the initial
ﬂuorescence F0, the average ﬂuorescence during 30 sec before
stimulation, and then plotted against time.
2.11. Cell Culture and Flow Cytometry. The endothelial cell
line EA.hy926 was cultured in DMEM containing 10% (v/v)
heat-inactivated FBS, and the antibiotics, penicillin, and
streptomycin (100 IU/mL) at 37°C in humidiﬁed air with
5% CO2. Cells were harvested using trypsin/EDTA and
incubated at 106 cells/mL with 100μg/mL of B. lanceolatus
venom, for 2 h at 37°C under constant agitation. Cells were
centrifuged at 400×g and resuspended in FACS buﬀer.
Cells (5× 104 cells/well) were incubated for 1 h at 4°C with
monoclonal antibodies anti-human MCP, DAF, or CD59
(1μg/mL), followed by incubation with goat anti-mouse
IgG-PE (1 : 100), for 1 h at 4°C. Cells were analysed by ﬂow
cytometry (FACSCanto-II, Becton Dickinson, San Diego,
CA, USA) using the software FACSDiva (Becton Dickinson,
San Diego, CA, USA).
2.12. Statistics. Numerical data were expressed as mean± SD.
Data were analysed statistically by Student’s t-test, or by
one way ANOVA and Bonferroni’s multiple comparison
test, using the software GraphPad Prism 6 (GraphPad
Software, Inc., La Jolla, CA, USA). A P value< 0.05 was
considered signiﬁcant.
3. Results
3.1. B. lanceolatus Venom Aﬀects All Three Complement
Activation Pathways. Human serum (NHS) was incubated
with B. lanceolatus venom and residual haemolytic activity
was assessed. As shown in Figures 1(a) and 1(b), the venom
dose-dependently reduced the lytic activity of CP and AP of
NHS. The venom aﬀected the classical pathway with an
IC50 of 156.6μg/mL (CI95%: 147.3–166.6μg/mL) and the
alternative pathway with an IC50 of 294.5μg/mL (CI95%:
273.2–317.4μg/mL) (Figures 1(a) and 1(b)). The venom also
aﬀected the C4 deposition in the LP assay, resulting in an IC50
of 396.3μg/mL (CI95%: 375.7–418.0μg/mL) (Figure 1(c)).
3.2. B. lanceolatus Venom Generates C4a and C5a and TCC in
NHS but Reduces C3a. To establish whether the observed
reduction C-activity resulted from inhibition or activation
(resulting in consumption) of the Complement cascade by
the venom, the presence of anaphylatoxins and terminal
Complement complex (TCC) in venom-treated NHS sam-
ples was investigated. Figure 2 reveals that B. lanceolatus
venom induces a signiﬁcant production of C4a, C5a, and
TCC, thus conﬁrming direct activation of the Complement
system by the venom. Surprisingly, the venom caused a sig-
niﬁcant decrease of C3a in the serum, when compared with
the control. These activities were inhibited with the addition
of a metalloprotease inhibitor, 1,10-phenantroline, suggest-
ing the participation of B. lanceolatus venom metallopro-
teases in Complement activation.
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Figure 1: Activation of the three Complement pathways by B. lanceolatus venom. NHS (dilution 1 : 80 (a), 1 : 4 (b), and 1 : 25 (c)) was
incubated with several concentrations of B. lanceolatus venom at 37°C for 1 h (CP) or 30min (AP and LP), and diluted to test their
residual Complement activity. NHS incubated only with buﬀer was used as control. (a) Sensitized sheep erythrocytes were used to assess
the CP while (b) rabbit erythrocytes (ER) were used for the AP. (c) For the LP, residual binding of C4 on a mannan-coated plate was used.
The results represent mean± SD of duplicates of a representative assay. Experiments were performed three times. The CH50, AP50, and
LP50 were calculated by nonlinear regression from these curves. The IC50 of the venom for each pathway and respective CI95% were
calculated. The venom aﬀected the classical pathway with an IC50 of 156.6 μg/mL of NHS (CI95%: 147.3–166.6μg/mL of NHS), the
alternative pathway with an IC50 of 294.5μg/mL of NHS (CI95%: 273.2–317.4μg/mL of NHS), and the LP pathway with an IC50 of
396.3μg/mL of NHS (CI95%: 375.7–418.0μg/mL of NHS).
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3.3. B. lanceolatus Venom Cleaves Puriﬁed C3, C4, and C5
and Generates Active C5a. Potential direct proteolytic action
of the venom on the Complement components were inves-
tigated using puriﬁed C3, C4, and C5 and incubations
with B. lanceolatus venom, in the presence or absence of
proteases inhibitors. SDS-PAGE (Figures 3 and 4) shows
that the venom reduced the intensity of staining of the
α-chains of C3, C4, and C5 while generating fragments
of slightly lower molecular mass, a pattern similar to what
is usually observed when these molecules are activated via
any of the Complement cascade. β- and γ-chains were not
signiﬁcantly aﬀected.
To further investigate if the C5a fragment produced by
the direct action of venom was functional, we measured its
ability to activate leukocytes, by means of monitoring the
calcium inﬂux induced by C5a in these cells. Neutrophils
constitute the major cell type in the leukocyte preparations
and are the main and strongest responders to C5a in leuko-
cyte preparations. Leukocytes, preloaded with the calcium
sensor Fluo-4 AM, were exposed to venom-treated C5
samples. Figure 3(d) demonstrates that venom-treated C5,
similar to puriﬁed C5a, is able to induce a calcium inﬂux in
leukocytes, demonstrating that functionally active C5a was
generated. Venom on its own or puriﬁed C5 on its own, did
not induce a change in intracellular calcium.
3.4. B. lanceolatus Venom Cleaves and Partially Inactivates
C1-INH. We previously showed that venoms from a range
of Bothrops snakes caused the cleavage of C1-INH, the solu-
ble regulator of the classical and lectin pathways. We show
here that B. lanceolatus venom also has that ability
(Figure 4). Both silver-staining (Figure 4(a)) and Western
blotting (Figure 4(b)) showed that the single-chain C1-INH
(reported to have a Mr of 105 kDa [38]) was reduced in Mr
by the venom action (with a reduction in size to approxi-
mately 98 kDa). This activity was totally inhibited by the
metalloprotease inhibitors, EDTA and 1,10-phenantroline,
whereas the inhibition displayed by the serine protease
inhibitor, PMSF, was partial (Figures 4(a) and 4(b)). Using
a functional ELISA assay testing the binding of C1s, we
observed that the venom-generated C1-INH fragments had
a reduced binding activity to C1s (Figure 4(c)), as compared
to the nonvenom-treated puriﬁed component, indicating
that it was inactivated by the venom.
3.5. B. lanceolatus Venom Does Not Reduce Expression of
Membrane-Bound C-Regulators. The Complement system
also includes regulatory proteins present on the cell mem-
branes, and reduction in expression on endothelial cells
would make cells more susceptible to C-induced activation.
Using the endothelial cell line EA.hy926, we investigated
the eﬀects of B. lanceolatus venom on the expression of
membrane-bound C-regulators DAF, MCP, and CD59. The
venom signiﬁcantly increased the expression of MCP and
CD59 and did not aﬀect DAF expression (Figure 5).
4. Discussion
B. lanceolatus, commonly called the Martinique lancehead
and Martinican pit viper, is the only endemic snake on
Martinique [1, 2]. Clinical presentations of envenomations
by B. lanceolatus are characterized by systemic thrombotic
syndrome and important local inﬂammation, involving
oedema and pain, but limited haemorrhage.
The Complement system is an important contributor to
and ampliﬁcator of inﬂammation if activated in excess or
inappropriately controlled. Anaphylatoxins generated as a
consequence of C activation are major contributors to the
inﬂammation. The Complement system can also contribute
to thrombosis by activating endothelial cells and contributing
to platelet activation, and both anaphylatoxins and the TCC
are contributors [27]. In this study, we analysed the action
of B. lanceolatus venom on the Complement system activa-
tion pathways, components, regulators, and receptors. We
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Figure 2: Production of Complement activation products in NHS incubated with B. lanceolatus venom. NHS (diluted 1 : 2 in saline solution)
was incubated with B. lanceolatus venom (0.5mg/mL) for 30min at 37°C, in the presence or absence of 1,10-phenantroline (10mM). As
control, NHS was incubated with saline solution. (a) Samples were diluted 1 : 5000 and the concentrations of the anaphylatoxins C3a/C3a-
desArg, C4a/C4a-desArg, and C5a/C5a-desArg were determined using a cytometric bead array. (b) Samples were diluted 1 : 150, and the
concentration of the SC5b-9 complex was measured by “MicroVue SC5b-9 Plus EIA Kit”. The data represent two experiments, realized in
duplicate. ∗p < 0 05 compared to the saline-treated NHS controls. #p < 0 05 compared to venom-treated samples.
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show here that the venom can activate all three Complement
pathways (Figure 1). Activation of the AP may be simply a
consequence of activation of the LP and CP, which often also
results in activation of the AP, which then acts as an
ampliﬁcation loop. Recently, we have demonstrated the
presence of glycosylated proteins in this venom [10], which
potentially are involved the lectin pathway activation;
however, this remains to be investigated.
Complement activation by B. lanceolatus venom was
also demonstrated by the detection of C-activation prod-
ucts, such as the anaphylatoxins C4a and C5a and TCC
(Figure 2). However, a decrease rather than an increase in
the concentration of C3a was detected in venom-treated
NHS. We have previously shown that out of venoms from
19 diﬀerent Bothrops species, 18 induced the generation of
C3a in serum, but similar to B. lanceolatus, the B. brazili
venom also induced a reduction in C3a [28]. These results
may be due to the presence of venom peptidases able to
further hydrolyse C3a. C3a is a potent proinﬂammatory
signal for several cell types, such as macrophages/mono-
cytes, peripheral nonadherent PBMCs, and mast cells [39].
In contrast to C5a, C3a does not directly activate neutrophils
and can prevent their mobilization from bone marrow to
the blood stream, which constitutes an anti-inﬂammatory
action in the early phase of inﬂammation [39–41]. Thus,
the reduction of C3a and the increase of C5a in B. lanceo-
latus venom may contribute to its potent proinﬂammatory
action. However, further kinetics studies analysing C3a
and C5a generation and degradation, are necessary to
deﬁne the possible consequences of these results in the
envenomation process.
Analysis of the contributions of metalloproteases,
common components of Bothrops venoms, showed that
the metalloprotease inhibitor 1,10-phenanthroline partially
or completely prevented the eﬀects of the venom on the
generation of anaphylatoxins and TCC in whole serum
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Figure 3: Cleavage of puriﬁed C3, C4, and C5 by B. lanceolatus venom. Samples (2 μg) of puriﬁed Complement components C3 (a), C4 (b),
and C5 (c) were incubated in PBS with B. lanceolatus venom (2 μg) for 30min at 37°C. The cleavage was visualized by electrophoretic
separation (10% acrylamide SDS-PAGE) under reducing conditions, followed by silver staining. (d) The functional activity of the
venom-treated C5 fragments was assessed via measuring calcium inﬂux in Fluo-4-AM-labelled leukocytes (5× 106 cells/mL). Puriﬁed
C5a (2.4 ng/mL) and samples of C5 or venom incubated with saline were used as positive and negative controls, respectively. Cells
were allowed to equilibrate for 60 sec before stimulation (arrow).
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(Figure 2), suggesting an important role for metallopro-
teases in the activation of the Complement system. The role
of serine proteases in this process cannot be investigated as
the enzymes in the Complement system themselves are
serine proteases.
Considering that Bothrops venoms contain a large
amount of proteases, we analysed the ability of B. lanceolatus
venom to directly cleave the sources of anaphylatoxins, such
as C3, C4, and C5. Data presented here show that venom
components can hydrolyse the α-chain of the three Com-
plement proteins (Figure 3). These fragments could partic-
ipate or be the origin of the potent activation of the three
pathways by the venom; however, their functional activity
remains to be tested. Puriﬁcation of venom components
would be required to investigate the identity of the compo-
nents responsible for Complement activation and enzymatic
cleavage of puriﬁed components.
We also show here that the C5a fragment, generated
through the degradation of puriﬁed C5 by B. lanceolatus
venom, is functionally active, demonstrating that venom
proteases directly cleave C5 into functional C5a
(Figure 3(d)). The cleavage of C5 after envenomation, due
to the generation of a C5-convertase, as a consequence
of the activation of the three Complement pathways, is
likely an important mechanism in the generation of C5a
(Figures 1 and 2). In addition, direct activation of C5a is a
possibility, and thrombin-like enzymes have already been
reported in Bothrops sp. venoms [42–44] and may be respon-
sible for the direct generation of C5a, since human thrombin
can cleave C5 into functional C5a. As activated human coag-
ulation proteins (e.g., thrombin, plasmin, FX, and FXIa) are
known to activate C5 [42, 45], further C5a could also be
generated. Considering that both C5a [46–48] and TCC
[49–51] can display several prothrombotic eﬀects, how these
two C-activation products contribute to the prothrombotic
pathology observed in B. lanceolatus envenomation requires
further investigation.
The C1-inhibitor, C1-INH, is the only known serine pro-
tease plasma inhibitor. It regulates not only the Complement
cascade (inhibitor of C1r, C1s, and MASPs) but is also an
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Figure 4: Cleavage of puriﬁed Complement regulator C1-INH by B. lanceolatus venom and its residual C1s-complexing activity. C1-INH
(2 μg) samples were incubated with B. lanceolatus venom (2 μg) for 30min at 37°C and the cleavage was visualized by SDS-PAGE
electrophoresis, followed by silver staining (a), or by Western blot using anti-C1-INH antibodies (b). The residual C1s-complexing activity
of the C1-INH fragments was assessed by functional ELISA (c). The results represent the mean of two independent experiments, carried
out in triplicates. Data are represented as mean± SD. ∗p < 0 05 between two samples.
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important regulator of the coagulation cascade activation
and inhibits several ﬁbrinolytic proteins (kallikrein, FXIIa,
FXIa, and plasmin) [52]. It inhibits the Complement serine
protease C1s by acting as a pseudosubstrate: C1-INH is
cleaved at the peptide-bound R444-T445 and forms a stable
complex with C1s via its residues Q452, Q453, and F455
[53]. A deﬁciency of C1-INH can result in autoactivation of
these pathways [54]. Our results reveal that B. lanceolatus
venom also cleaves puriﬁed C1-INH, mainly by metallo-
protease action, which may explain the activation of the
C-cascades. In conditions of complete C1-INH conversion
by B. lanceolatus venom, the C1s-inhibitory potential loss
was about 40%, similar to the value observed with B. pirajai
metalloprotease, C-SVMP, under comparable conditions
[32]. This loss of function could result from C1s-binding
site impairment by the venom. It could be related to the
activation of classical and lectin pathways by B. lanceolatus
venom. Furthermore, C1-INH is also an important regula-
tor of several proteins involved in the coagulation cascade
and dysfunction or deﬁciency of C1-INH can lead to excess
generation of bradykinin, a potent vasodilator and important
contributor to inﬂammation, and is associated with heredi-
tary angioedema (HAE) [52]. This may be the major mecha-
nism of how B. lanceolatus venom induces inﬂammation.
As Complement activation on endothelial cells can lead
to a more prothrombotic phenotype of these cells [55], endo-
thelial cells express Complement inhibitors on their mem-
brane, such as membrane cofactor protein (MCP/CD46),
decay-accelerating factor (DAF/CD55), and CD59 [56]. A
deﬁciency of MCP has been associated with atypical human
uraemic syndrome (aHUS) which is characterized by throm-
botic microangiopathies [57], while a deﬁciency of DAF/
CD59 is associated with paroxysmal nocturnal haemoglobi-
nuria (PNH), which also is associated with thrombosis [58].
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Figure 5: Eﬀect of B. lanceolatus venom exposure on C-regulator expression on endothelial cells. EA.hy926 cells (106 cells/mL) were
incubated with B. lanceolatus venom (100 μg/mL) for 2 h. After incubation with DAF-, MCP-, and CD59-speciﬁc antibodies, the
ﬂuorescence was assessed by ﬂow cytometry. The results are representative of two experiments, carried out in triplicates. Data are
represented as mean± SD. ∗p < 0 05 compared to the buﬀer-treated controls. #p < 0 05 between two samples.
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Furthermore, we previously reported the cleavage of MCP
induced by Loxosceles spider venom [59] and this might
contribute to the systemic thrombotic events associated with
envenomation. In our study, the B. lanceolatus venom did
not reduce expression of any of these regulators but, sig-
niﬁcantly, increased the detection of MCP and CD59
(Figure 5). Thus, increased thrombosis after B. lanceolatus
envenomation is unlikely due to ineﬃcient C regulation on
the endothelial cells, but endothelial activation in response
to excess C5a or TCC generation, as a consequence of the
eﬀect of the venom on the Complement system, may con-
tribute. Bothrops species venoms activate the Complement
cascade by several pathways and complex mechanisms
[28]. In the case of B. asper and B. pirajai venoms, class
I metalloproteases are involved [30, 32]. Since structural
similarities exist between Bothrops toxins, B. lanceolatus
PI-SVMPs may be involved in B. lanceolatus Complement
activation, but this remains to be investigated.
In conclusion, here we show that, like its continental
counterparts, B. lanceolatus venom is a potent trigger of the
Complement cascade in vitro. Thus, further in vivo studies
may support the idea that therapeutic management of sys-
temic B. lanceolatus envenomation could include the use of
Complement inhibitors as adjunct therapy.
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